All In MedTech

Device Trial Radar · NCT03702192

EXCOR® Pediatric VAD Anticoagulation IDE

EXCOR® Pediatric VAD Anticoagulation IDE Investigational Plan

Last checked: Nov 20, 2026Latest source record: Oct 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Nov 2018

Primary completion

Nov 2018

Study completion Jan 17, 2019

Sponsor

Lead sponsor
David N. RosenthalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 10, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
FDA-regulated device
Yes
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Berlin Heart EXCOR ventricular assist device received approval from the FDA as a bridge to transplantation for children in 2011. Successful bridge to transplantation or recovery in the IDE trial of the Berlin Heart EXCOR was 88% to 92%, but a high incidence of neurological injury was reported in this trial (29%). Stroke remains the most important complication of Berlin Heart EXCOR support, with high mortality rates, and considerable long-term morbidity. The EXCOR IDE study incorporated a novel anticoagulation protocol (henceforth referred to as the Edmonton Anticoagulation Protocol). The preponderance of ischemic strokes in this study raised the question of whether the anticoagulation protocol was sufficiently intensive, as ischemic strokes in this setting are virtually always thromboembolic phenomena. In response to these data and to the experience at the investigator's institution, a novel anticoagulation protocol has been devised for use with the EXCOR (Stanford anticoagulation protocol).The purpose of this study is to perform a pilot evaluation of this protocol in a multi--center setting, to prepare for a randomized trial between this and a subsequent iteration of anticoagulation treatment.

Conditions

  • Pediatric HD

Interventions

  • novel anticoagulation protocol used in conjunction with the Berlin Heart EXCORDevice

    novel antithrombotic management protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of major bleeding adverse events reported using the Stanford Anti-Thrombotic Protocol.Time frame: Up to 90 days
  2. Number of all forms of stroke events reported using the Stanford Anti-Thrombotic Protocol.Time frame: Up 90 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.